Good morning :)
$
₹
Bullfrog AI Holdings, Inc. Common Stock

Bullfrog AI Holdings, Inc. Common Stock

BFRG

NASDAQ
Asset Logo

Bullfrog AI Holdings, Inc. Common Stock

BFRG

NASDAQ
$0.487.46% (-0.03)
$
₹
$0.487.46% (-0.03)
High
—
—
Low
—
—
Returns
—
—
Loading...
1D
1W
1M
3M
6M
1Y
3Y
5Y
Max

Healthcare

Health Information Services

Micro Cap

With a market cap of $9.7M the stock is ranked 5745

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

—
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

1.31
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$-0.47
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

—
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

0%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

—

Analyst Ratings & Forecast

Analyst Ratings & Forecast

Detailed Forecast Detailed Forecast 

Based on consolidated analysts reports

?

Buy, Sell and Hold recommendations are not available

Price Upside

—

Earnings Growth

+42.09%

Rev. Growth

+568.55%

See Detailed Forecast

Company Profile

Company Profile

Bullfrog AI Holdings, Inc. operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. The company offers bfLEAP, an analytical AI/ML platform to analyze preclinical and clinical data for biotechnology and pharmaceutical companies, and other organizations. It also develops BF-222, a novel formulation of mebendazole, which is in the first phase for the treatment of Glioblastoma; BF-223, a novel prodrug of mebendazole, which is in the preclinical stage for the treatment of Glioblastoma; and BF-114, which is in the discovery phase, to treat obesity and chronic liver diseases. The company has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for use of a formulation of Mebendazole for the treatment of glioblastoma, and human cancer or neoplastic disease. It has a partnership with the Lieber Institute for Brain Development (LIBD) to enable the discovery and development of precision treatments for CNS disorders. The company was founded in 2017 and is headquartered in Gaithersburg, Maryland.
Bullfrog AI Holdings, Inc. operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. The company offers bfLEAP, an analytical AI/ML platform to analyze preclinical and clinical data for biotechnology and pharmaceutical companies, and other organizations. It also develops BF-222, a novel formulation of mebendazole, which is in the first phase for the treatment of Glioblastoma; BF-223, a novel prodrug of mebendazole, which is in the preclinical stage for the treatment of Glioblastoma; and BF-114, which is in the discovery phase, to treat obesity and chronic liver diseases. The company has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for use of a formulation of Mebendazole for the treatment of glioblastoma, and human cancer or neoplastic disease. It has a partnership with the Lieber Institute for Brain Development (LIBD) to enable the discovery and development of precision treatments for CNS disorders. The company was founded in 2017 and is headquartered in Gaithersburg, Maryland.

Peers

Compare with peers Compare with peers 

Peers

Compare with peers Compare with peers 
Abbott Laboratories
ABT
Abbott Laboratories
P/E Ratio
40.97
40.97
1Y Return
13.03%
13.03%
Buy Reco %
82.14
82.14
Danaher Corporation
DHR
Danaher Corporation
P/E Ratio
38.09
38.09
1Y Return
7.61%
7.61%
Buy Reco %
83.33
83.33
Intuitive Surgical Inc
ISRG
Intuitive Surgical Inc
P/E Ratio
53.29
53.29
1Y Return
10.52%
10.52%
Buy Reco %
76.47
76.47
Medtronic PLC
MDT
Medtronic PLC
P/E Ratio
24.41
24.41
1Y Return
16.08%
16.08%
Buy Reco %
66.66
66.66
Stryker Corporation
SYK
Stryker Corporation
P/E Ratio
32.68
32.68
1Y Return
6.33%
6.33%
Buy Reco %
76.66
76.66
Compare with Peers

Forecast

Forecast

Price

Revenue

Earnings

Revenue Forecast

Revenue Forecast

2025
Current$116.67Baseline
Forecast for Dec 2026
High$780+568.55%
Average$780+568.55%
Low$780+568.55%

All values in $ Thousand

202120222023202420252026010650116.67Low+568.55%Average+568.55%High+568.55%
2025
Current$116.67Baseline
Forecast for Dec 2026
High$780+568.55%
Average$780+568.55%
Low$780+568.55%

All values in $ Thousand

Earnings Per Share Forecast

Earnings Per Share Forecast

2025
Current$-0.64Baseline
Forecast for Dec 2026
High$-0.37+42.09%
Average$-0.37+42.09%
Low$-0.37+42.09%

All values in $

20222023202420252026N/A-0.91-0.86-0.64Low+42.09%Average+42.09%High+42.09%
2025
Current$-0.64Baseline
Forecast for Dec 2026
High$-0.37+42.09%
Average$-0.37+42.09%
Low$-0.37+42.09%

All values in $

Financials

Financials

Income

Balance Sheet

Cash Flow

0
-1.5
-1.4
-1.5
0.2
-1.3
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Revenue
Net Income
Financial YearQ1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026
Total Revenue000000.030.08000.21
Net Income-1.90-1.61-1.76-1.71-2.01-1.44-1.55-1.48-1.59-1.37
Net Profit Margin----99463.05%--4356.16%-1860.15%---636.78%
See CostsAll values in $ Million

Peers

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareHealth Information Services

Valuation

Returns

Forecast

ScreenerCompare valuation on Screener
StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
Bullfrog AI Holdings, Inc. Common Stock -1.31-
Abbott Laboratories40.973.721.57
Danaher Corporation38.092.981.29
ScreenerCompare valuation on Screener

Price Comparison

Price Comparison

Compare BFRG with any stock or ETF
Compare BFRG with any stock or ETF
Comparing from
BFRG
ABT
DHR
Loading...

Frequently asked questions

  1. Bullfrog AI Holdings, Inc. Common Stock (BFRG) share price today is $0.48 as of November 6, 2026 at 1:08 AM IST. The stock touched a day high of $0.54 and a day low of $0.47.

  2. Bullfrog AI Holdings, Inc. Common Stock stock trades on NASDAQ under the ticker symbol BFRG.

  3. Bullfrog AI Holdings, Inc. Common Stock's market capitalization is $9.7M as of November 6, 2026 at 1:08 AM IST.

  4. Bullfrog AI Holdings, Inc. Common Stock's price-to-earnings (P/E) ratio is N/A as of November 5, 2026.

  5. Bullfrog AI Holdings, Inc. Common Stock's price-to-book (P/B) ratio is 1.31 as of November 5, 2026.

  6. Yes, You can buy Bullfrog AI Holdings, Inc. Common Stock shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  7. Indian investors can buy Bullfrog AI Holdings, Inc. Common Stock shares in three steps: 1. Search Bullfrog AI Holdings, Inc. Common Stock on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  8. Since Bullfrog AI Holdings, Inc. Common Stock trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  9. Indian investors can start investing in Bullfrog AI Holdings, Inc. Common Stock (BFRG) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 20.5338 shares at the current price of $0.48.

Loading...